Aggrelytes for treating ocular conditions

US12350250B2 · kind B2 · utility

Assignee

• The Regents of the University of Colorado, a Body Corporate · US

Inventors

• Ram H. Nagaraj · Aurora, US
• Rooban B. Nahomi · Aurora, US
• Sandip Nandi · Sernabatim, IN

Key dates

• Filing date: Mar 31, 2023
• Grant date: Jul 8, 2025
• Expiry date: Apr 4, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P27/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treating, preventing, delaying, or reversing presbyopia in a subject involve administering a pharmaceutically effective amount of an aggrelyte to the subject. The aggrelyte may be one or more of N,S-diacetyl-L-cysteine methyl ester, S-acetyl-N-(3,3,-dimethylbutanoyl)-L-cysteinate, or N-acetyl cysteine methyl ester. The aggrelyte may be administered topically.